FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Petra Ohneseit

Research Profile

Anatomy

Phenomena

Physiology

Disorders

Genes & Molecular Sequences

Genes, p53

Chemicals & Drugs

Procedures

Immunohistochemistry

Concepts & Ideas

Radiation Dose-Response Relationship

Co-author Network

Publications

TOP 3
Hassan Chaachouay; Rainer Kehlbach; Gabriele Multhoff; Petra A Ohneseit; Mahmoud Toulany; H Peter Rodemann
Autophagy contributes to resistance of tumor cells to ionizing radiation.
Stephan Kruck; Jens Bedke; Jörg Hennenlotter; Petra A Ohneseit; Ursula Kuehs; Erika Senger; Karl-Dietrich Sievert; Arnulf Stenzl
Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Jörg Hennenlotter; Petra A Ohneseit; Perikles Simon; Axel S Merseburger; Jürgen Serth; Ursula Kuehs; Mario Kramer; Joerg T Hartmann; Arnulf Stenzl; Markus A Kuczyk
PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas--implications for Akt activation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Petra Ohneseit (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2011: Hassan Chaachouay; Rainer Kehlbach; Gabriele Multhoff; Petra A Ohneseit; Mahmoud Toulany; H Peter Rodemann
Autophagy contributes to resistance of tumor cells to ionizing radiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2011;99(3):287-92.
2010: Stephan Kruck; Jens Bedke; Jörg Hennenlotter; Petra A Ohneseit; Ursula Kuehs; Erika Senger; Karl-Dietrich Sievert; Arnulf Stenzl
Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
Oncology reports 2010;23(1):159-63.
2008: Jörg Hennenlotter; Petra A Ohneseit; Perikles Simon; Axel S Merseburger; Jürgen Serth; Ursula Kuehs; Mario Kramer; Joerg T Hartmann; Arnulf Stenzl; Markus A Kuczyk
PTEN and p27Kip1 are not downregulated in the majority of renal cell carcinomas--implications for Akt activation.
Oncology reports 2008;19(5):1141-7.
2008: Klaus Dittmann; Claus Mayer; Petra A Ohneseit; Uma Raju; Nicolaus Andratschke; Luka Milas; H Peter Rodemann
Celecoxib induced tumor cell radiosensitization by inhibiting radiation induced nuclear EGFR transport and DNA-repair: a COX-2 independent mechanism.
International journal of radiation oncology, biology, physics 2008;70(1):203-12.
2007: Petra A Ohneseit; Guido Krebiehl; Klaus Dittmann; Rainer Kehlbach; H Peter Rodemann
Inhibition of cyclooxygenase-2 activity by celecoxib does not lead to radiosensitization of human prostate cancer cells in vitro.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2007;82(2):229-38.
2005: Axel S Merseburger; Jörg Hennenlotter; Perikles Simon; Petra A Ohneseit; Ursula Kuehs; Stephan Kruck; Eva Koch; Ulrich Vogel; Arnulf Stenzl; Markus A Kuczyk
Cathepsin D expression in renal cell cancer-clinical implications.
European urology 2005;48(3):519-26.
2005: Petra A Ohneseit; Daniela Prager; Rainer Kehlbach; H Peter Rodemann
Cell cycle effects of topotecan alone and in combination with irradiation.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2005;75(2):237-45.
2002: Petra A Ohneseit; A Wildemann; Carsten Herskind; D D; H Peter Rodemann
Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
International journal of radiation biology 2002;78(2):125-32.
2001: ME Schiebe; Petra A Ohneseit; W Hoffmann; R Meyermann; H P Rodemann; D D
Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas.
Journal of cancer research and clinical oncology 2001;127(5):325-8.
2000: ME Schiebe; Petra A Ohneseit; W Hoffmann; Richard Meyermann; H Peter Rodemann; D D
Analysis of mdm2 and p53 gene alterations in glioblastomas and its correlation with clinical factors.
Journal of neuro-oncology 2000;49(3):197-203.
1998: Klaus Dittmann; Nuri Gueven; Claus Mayer; Petra A Ohneseit; R Zell; A C Begg; H Peter Rodemann
The presence of wild-type TP53 is necessary for the radioprotective effect of the Bowman-Birk proteinase inhibitor in normal fibroblasts.
Radiation research 1998;150(6):648-55.